Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-2.92%
-2.08%
-3.34%
+9.79%
-19.01%
TEVA
Teva Pharma
$16.78
Chart
$13.31 (+26.07%)
$15.35 (+9.32%)
$21.79 (-22.99%)
$17.16 (-2.21%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-2.92%
-2.08%
-3.34%
+9.79%
-19.01%
TEVA
Teva Pharma
Current Price
$16.78
Login to view Teva Pharma (TEVA) recommendation from the last 90 days from financial news and social media.
Chart
$13.31 (+26.07%)
$15.35 (+9.32%)
$21.79 (-22.99%)
$17.16 (-2.21%)
TEVA Latest Headlines
Teva Reaffirms Growth Strategy Eyes $5 Billion Innovative Franchise By 2030. Israeli multinational pharmaceutical company ) hosted 2025 Innovation &. Strategy Day on Thursday to launch the acceleration phase of its “.Pivot to Growth”. strategy and to discuss portfolio priorities.The company outlined its plan to evolve into a leading biopharmaceutical company emphasizing its innovative medicines franchise and a strong generics and biosimilars portfolio.President and CEO Francis highl
Thu May 29, 2025
Global Smart Inhalers Market to Observe Impressive Growth at a CAGR of ~21% by 2032 | DelveInsight. Global Smart Inhalers Market to Observe Impressive Growth at a CAGR of ~21% by 2032 |. DelveInsightThe smart inhalers market is experiencing significant growth driven by the increasing incidence of respiratory diseases like asthma and COPD technological advancements widespread smartphone usage and a growing awareness of digital health solutions. These factors are expected to fuel strong demand
Thu May 29, 2025
Teva Reaffirms Pivot to Growth Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day.
Thu May 29, 2025
Where Teva Pharmaceutical Indus Stands With Analysts. In the last three months 4 analysts have published ratings on Teva Pharmaceutical Indus (NYSE:) offering a diverse range of perspectives from ish to bearish.Summarizing their recent assessments the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.3100010000110000000010000Analysts have recently evaluated Teva Pharmaceutical Indus and provided 12-month price targets. The average targe
Wed May 28, 2025
Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June. TEL AVIV Israel May 27 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that members of its executive management team will present at two upcoming investor conferences in June as follows:
Tue May 27, 2025
Why Is Teva Stock Trading Higher On Tuesday?. ) and Biolojic Design Ltd announced that Teva initiated IND-enabling studies with BD9 a dual-specific multibody targeting both TSLP (Thymic stromal .Teva has an exclusive license to develop BD9 for TH2-driven inflammatory diseases such as .By simultaneously blocking two key drivers of TH2-driven inflammation BD9 can potentially improve outcomes for patients with conditions such as atopic dermatitis and asthma where current treatments fall short.Also
Tue May 27, 2025
Why Is Teva Stock Trading Higher On Tuesday?. ) and Biolojic Design Ltd announced that Teva initiated IND-enabling studies with BD9 a dual-specific multibody targeting both TSLP (Thymic stromal .Teva has an exclusive license to develop BD9 for TH2-driven inflammatory diseases such as .By simultaneously blocking two key drivers of TH2-driven inflammation BD9 can potentially improve outcomes for patients with conditions such as atopic dermatitis and asthma where current treatments fall short.Also
Tue May 27, 2025
Teva Announces Successful Upsizing and Pricing of $2300000000 (Equivalent) Senior Notes. Proceeds to Repay Existing Debt. . Alternatively a copy of the prospectus supplement and accompanying base prospectus related to this offering may be obtained when available by contacting BNP PARIBAS 16 boulevard des Italiens 75009 Paris France Attention: High Yield Desk (email: ). BNP Paribas Securities Corp. 787 Seventh Avenue New York New York 10019 United States of America Attention: Syndicate Desk (emai
Tue May 20, 2025
Fitch Ratings Agency Upgrades Teva Rating to BB Recognizing Successful Execution of Its Pivot to Growth Strategy. FITCH RATINGS AGENCY UPGRADES TEVA RATING TO BB RECOGNIZING SUCCESSFUL EXECUTION OF ITS PIVOT TO GROWTH STRATEGY
Tue May 20, 2025
Fitch Ratings Agency Upgrades Teva Rating to BB Recognizing Successful Execution of Its Pivot to Growth Strategy. FITCH RATINGS AGENCY UPGRADES TEVA RATING TO BB RECOGNIZING SUCCESSFUL EXECUTION OF ITS PIVOT TO GROWTH STRATEGY
Tue May 20, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
TEVA Stock trends
TEVA Stock performance
TEVA Stock analysis
TEVA investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
